James McNutt
Acute Care · Clearwater, FLNPI 1790088623
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,711 of the $6,391 with a category attached, or 73.7%. 27 manufacturers reported payments, led by Sanofi at 33.2% of the total. 2025 is the largest year on record at $5,293, more than ten times the $122 reported in 2021. Among acute care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $28.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- GSK$682
- AstraZeneca$572
- Insmed, Inc.$503
- Grifols USA, LLC$243
- AbbVie$228
- plus $2K from 21 others
What the payments were for
- Consulting fees$1,43422%
- Food & beverage$4,71174%
- Education$2464%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 14 | $2,122 |
| GSK | 35 | $682 |
| AstraZeneca | 28 | $572 |
| Insmed, Inc. | 40 | $503 |
| Grifols USA, LLC | 11 | $243 |
| AbbVie | 10 | $228 |
| Amgen | 12 | $210 |
| Boehringer Ingelheim | 13 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $177 |
| Merck | 6 | $174 |
| Regeneron Healthcare Solutions, Inc. | 5 | $169 |
| Bayer | 8 | $162 |
| Actelion Pharmaceuticals US, Inc. | 5 | $160 |
| Sanofi-aventis U.S. LLC | 2 | $147 |
| Harmony Biosciences LLC | 5 | $136 |
| United Therapeutics Corporation | 6 | $134 |
| Verona Pharma, Inc. | 4 | $82 |
| Electromed, Inc. | 4 | $57 |
| Itamar Medical Inc | 1 | $54 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Jazz Pharmaceuticals Inc. | 1 | $33 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Pulmonx Corporation | 1 | $20 |
| Novartis | 1 | $20 |
| Shionogi Inc | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Inogen, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$122
- DUPIXENT$112
How this compares
$6,391 in reported general payments places this provider in the 95th percentile of 1,150 acute care providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $64,646 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $11,297 |
| Spiriva RespimatTiotropium Bromide | 14 | $9,975 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $9,920 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $7,399 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,150 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 184 | $4,761 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,050 |
| Ventolin HfaAlbuterol Sulfate | 11 | $710 |
| Doxycycline Hyclate | 22 | $208 |
| Azithromycin | 14 | $202 |
| Fluticasone Propionate | 13 | $174 |
| Prednisone | 40 | $138 |
| Omeprazole | 11 | $110 |
| Montelukast Sodium | 13 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $682 | $78,195107 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $191 | $21,27335 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $572 | $12,97029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,150 acute care providers in Florida.
Other acute care in Clearwater
- Melisa WilsonOrlando$214K
- Amanda PeacockJacksonville$81K
- Katrina RileyTampa$66K
- Diane GrayLake Mary$49K
- Heather RamousSafety Harbor$38K
- Melanie WeresJacksonville$37K
- Jayne JaramilloJacksonville$27K
- Melissa HamiltonTampa$23K
- Kimberly GrantAltamonte Springs$20K
- Julie ElliottWinter Haven$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.